Rodman & Renshaw initiated coverage of BioAtla (BCAB) with a Buy rating and $4 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/13/25
- BioAtla Creates Super-Voting Share to Advance Reverse Split
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/12/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/9/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/8/25